The renin-angiotensin system in mitral regurgitation: A typical example of tissue activation

Current Cardiology Reports

Volumn 4, Issue 2, 2002, Pages 97-103

  Dell'Italia, Louis J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERINE PROTEINASE;

ANIMAL; ANIMAL MODEL; DOG; DRUG ANTAGONISM; HEMODYNAMICS; HUMAN; MITRAL VALVE REGURGITATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHYMASES; DOGS; HEMODYNAMIC PROCESSES; HUMANS; MITRAL VALVE INSUFFICIENCY; MODELS, ANIMAL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SERINE ENDOPEPTIDASES;

EID: 0036517182     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0020-x     Document Type: Article

References (50)

1. Pitt B, Poole-Wilson PA, Segal R, et al., on behalf of the ELITE II investigators: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 55:1582-1587.
2. Konstam MA, Patten RD, Thomas I, et al.: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000, 139:1081-1087.
3. Konstam M, Kronenberg MW, Rousseau MF, et al., for the SOLVD investigators: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe heart failure. N Engl J Med 1987, 316:1429-1431.
5. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1991, 327:685-691.
6. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:292-302.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
8. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669-677.
9. Yusuf S, Pepine CJ, Garces C, et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173-1178.
10. Carabello BA, Nakano K, Corin W, et al.: Left ventricular function in experimental volume overload hypertrophy. Am J Physiol 1989, 256:H974-H981.
11. Scoglamiglio R, Rahimtoola SH, Fasoli G, et al.: Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994, 331:689-694.
12. Levine HJ, Gaasch WH: Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996, 28:1083-1091.
13. Carabello BA, Crawford FA Jr: Valvular heart disease. N Engl J Med 1997, 337:32-41.
14. Dzau VJ: Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989, 7:933-936.
15. Mento PF, Wilkes BM: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987, 9:III42-III48.
16. Baruch L, Anand I, Cohen IS, et al., for the Vasodilator Heart Failure Trial (V-HeFT) Study Group: Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999, 99:2658-2664.
17. Jorde UP, Ennezat PV, Lisker J, et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000, 101:844-846.
18. Urata H, Healy B, Stewart RW, et al.: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990, 66:883-890.
19. Urata H, Kinoshita A, Misono KS, et al.: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990, 265:22348-22357.
20. Urata H, Kinoshita A, Perez DM, et al.: Cloning of the gene and cDNA for human heart chymase. J Biol Chem 1991, 266:17173-17179.
21. Dell'Italia LJ, Husain A: Chymase: a critical evaluation of its role in angiotensin II formation and cardiovascular disease. In Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery. Edited by A Husain, RM Graham. London: Harwood Academic; 2000.
22. Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.
23. Dell'Italia LJ, Meng QC, Balcells E, et al.: Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol 1995, 269:H2065-H2073.
24. Zisman LS, Abraham WT, Meixell GE, et al.: Angiotensin II formation in the intact human heart. J Clin Invest 1995, 95:1490-1498.
25. Studer R, Reinecke H, Muller B, et al.: Increased angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest 1994, 94:301-310.
26. Dell'Italia LJ, Balcells E, Meng QC, et al.: Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997, 273:(Heart Circ Physiol 42)H961-H970.
27. Su X, Wei C-C, Machide N, et al.: Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation. J Mol Cell Cardiol 1999, 31:1033-1045.
28. Wei CC, Su X, Bishop SP, et al.: Afterload reduction and blockade of tissue renin angiotensin system does not improve left ventricular and cardiomyocyte remodeling in chronic mitral regurgitation. Circulation 1999, 100:I-863.
29. Dujardin KS, Enriquez-Sarano M, Bailey KR, et al.: Effect of losartan on degree of mitral regurgitation quantified by echocardiography. Am J Cardiol 2001, 87:570-576.
30. Wisenbaugh T, Essop R, Rothlisberger C, Sareli P: Effects of a single oral does of captopril on left ventricular performance in severe mitral regurgitation. Am J Cardiol 1992, 69:348-353.
31. Rothisberger C, Sareli P, Wisenbaugh T: Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation. Am J Cardiol 1994, 73:978-981.
32. Wisenbaugh T, Sinovich V, Dullbh A, Sareli P: Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 1994, 3:197-204.
33. Marcotte F, Honos G, Walling A, et al.: Effect of angiotensin converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol 1997, 13:479-485.
34. Host U, Kelbaek H, Hildebrandt P, et al.: Effect of Ramipril on mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 1997, 80:655-658.
35. Tischler M, Rowan M, LeWinter M: Effect of Enalapril on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 1998, 82:242-245.
36. Weber KT: Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997, 96:4065-4082.
37. Brilla CG, Matsubara L, Weber KT: Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996, 28:269-275.
38. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000, 102:1388-1393.
39. Caulfield JB, Wolkowicz PE: Myocardial connective tissue alterations. Toxicol Pathol 1990, 18:488-496.
40. Janicki JS, Campbell SE, Henegar JR, Brower BL: Myocardial interstitial collagen matrix remodeling in response to a chronic elevation in ventricular preload and afterload. In Cardiac-Vascular Remodeling and Functional Interaction. Edited by Maruyama Y, Hori M, Janicki JS. Tokyo: Springer-Verlag; 1997:19-31.
41. Stewart JA, Wei C-C, Lucchesi PA, et al.: Differential activation of ACE and chymase during early and late phases of left ventricular remodeling in response to the volume overload of mitral regurgitation. Circulation 2000, 102:II-131.
42. Dell'Italia LJ, Oparil S: Bradykinin in the heart: friend or foe? Circulation 1999, 100:2305-2307.
43. Brilla C, Zhou G, Rupp H, et al.: Role of angiotensin II and prostaglandin E sub 2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 1995, 76:8D-13D.
44. Nagatoma Y, Carabello BA, Coker ML, et al.: Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol 2000, 278:H151-H161.
45. Imamura T, McDermott PJ, Kent RL, et al.: Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload. Circ Res 1994, 75:418-425.
46. Urabe Y, Mann DL, Kent RL, et al.: Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation. Circ Res 1992, 70:131-147.
47. Nagatsu M, Zile MR, Tsutsui H, et al.: Native (-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. Circulation 1994, 89:818-826.
48. Mann DL, Kent RL, Parsons B, Cooper G: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
49. Mehta RH, Supiano MA, Oral H, et al.: Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implication in patients with mitral regurgitation. Am J Cardiol 2000, 86:1193-1197.
50. Tsutsui H, Spinale FG, Nagatsu M, et al.: Effects of chronic (-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994, 93:2639-2648.